Assessment of the Phenotypic Severity of Hemophilia A: Using Rotational Thromboelastometry (ROTEM) and APTT-clot Waveform Analysis

Overview

Journal Blood Res

Publisher Springer Nature

Specialty Hematology

Date 2024 May 14

PMID 38743166

Authors

Deepika Gupta

Vandana Arya

Jasmita Dass

Nitin Gupta

Manas Kalra

Anupam Sachdeva

Jyoti Kotwal

Affiliations

Soon will be listed here.

Abstract

Background: Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by reduced factor VIII (FVIII) levels. Approximately 10-15% of patients with severe HA (SHA) do not present with the anticipated bleeding pattern. Here, we assessed the phenotypic severity of hemophilia A using rotational thromboelastometry (ROTEM) and activated partial thromboplastin time-clot waveform analysis (APTT-CWA).

Methods: Patients diagnosed with hemophilia A were enrolled. Clinical phenotype assignment was performed according to the published literature, and patients were classified into four phenotypic subgroups. The whole blood sample was first run on ROTEM in INTEM mode using platelet-poor plasma, APTT was run, and the APTT-CWA graph was simultaneously recorded.

Results: A total of 66 patients were recruited for this study. Statistically significant differences were observed between the four phenotypically categorized groups using ROTEM and APTT-CWA. On comparing patients with mild/moderate-to-severe phenotypes (Group II) with SHA without inhibitors (Group IV), no significant difference was found for all parameters of ROTEM or APTT-CWA. The MCF, MA30, MAXV, and Alpha angle values using ROTEM were found to be the lowest in patients with SHA with inhibitors, which helped differentiate them from those with SHA without inhibitors. However, these two groups could not be differentiated using the APTT-CWA parameters.

Conclusion: ROTEM can be used to distinguish patients with SHA with inhibitors from those with SHA without inhibitors using a combination of parameters with high sensitivity and specificity. However, APTT-CWA cannot be used to differentiate these patient groups.

References

Chitlur M, Warrier I, Rajpurkar M, Hollon W, Llanto L, Wiseman C . Thromboelastography in children with coagulation factor deficiencies. Br J Haematol. 2008; 142(2):250-6. DOI: 10.1111/j.1365-2141.2008.07063.x. View

Aghighi S, Riddell A, Lee C, Brown S, Tuddenham E, Chowdary P . Global coagulation assays in hemophilia A: A comparison to conventional assays. Res Pract Thromb Haemost. 2020; 4(2):298-308. PMC: 7040542. DOI: 10.1002/rth2.12295. View

Nair S, Dargaud Y, Chitlur M, Srivastava A . Tests of global haemostasis and their applications in bleeding disorders. Haemophilia. 2010; 16 Suppl 5:85-92. DOI: 10.1111/j.1365-2516.2010.02304.x. View

Rodgers S, Duncan E . Chromogenic Factor VIII Assays for Improved Diagnosis of Hemophilia A. Methods Mol Biol. 2017; 1646:265-276. DOI: 10.1007/978-1-4939-7196-1_21. View

Matsumoto T, Nogami K, Shima M . A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. Int J Hematol. 2016; 105(2):174-183. DOI: 10.1007/s12185-016-2108-x. View

van den Berg H, De Groot P, Fischer K . Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007; 5 Suppl 1:151-6. DOI: 10.1111/j.1538-7836.2007.02503.x. View

Potgieter J, Damgaard M, Hillarp A . One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015; 94 Suppl 77:38-44. DOI: 10.1111/ejh.12500. View

Shima M, Thachil J, Nair S, Srivastava A . Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost. 2013; 11(7):1417-20. DOI: 10.1111/jth.12287. View

Vosough F, Ahmadinejad M, Toogeh G, Karimi K, Homayoun S, Managhchi M . Discrepancy between the results of one-stage and chromogenic factor VIII: C assays in patients with mild/moderate hemophilia A. Blood Coagul Fibrinolysis. 2020; 31(8):530-535. DOI: 10.1097/MBC.0000000000000959. View

10.

Matsumoto T, Nogami K, Tabuchi Y, Yada K, Ogiwara K, Kurono H . Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A. Haemophilia. 2017; 23(5):e427-e435. DOI: 10.1111/hae.13266. View

11.

Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K . The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost. 2002; 87(3):436-41. View

12.

Whiting D, DiNardo J . TEG and ROTEM: technology and clinical applications. Am J Hematol. 2013; 89(2):228-32. DOI: 10.1002/ajh.23599. View

13.

Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M . Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015; 13(7):1279-84. DOI: 10.1111/jth.12987. View

14.

Tarandovskiy I, Balandina A, Kopylov K, Konyashina N, Kumskova M, Panteleev M . Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res. 2013; 131(6):e274-80. DOI: 10.1016/j.thromres.2013.04.004. View

15.

Nogami K . The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016; 174(4):503-14. DOI: 10.1111/bjh.14148. View

16.

Sevenet P, Depasse F . Clot waveform analysis: Where do we stand in 2017?. Int J Lab Hematol. 2017; 39(6):561-568. DOI: 10.1111/ijlh.12724. View

17.

Coppola A, Di Capua M, Di Minno M, Di Palo M, Marrone E, Ierano P . Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med. 2012; 1:183-95. PMC: 3262316. DOI: 10.2147/JBM.S6885. View

18.

Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y . The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006; 4(2):377-84. DOI: 10.1111/j.1538-7836.2006.01730.x. View